GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Contineum Therapeutics Inc (NAS:CTNM) » Definitions » Goodwill-to-Asset

CTNM (Contineum Therapeutics) Goodwill-to-Asset : 0.00 (As of Sep. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Contineum Therapeutics Goodwill-to-Asset?

Goodwill to Asset ratio measures how much goodwill a company is recording compared to the total level of its assets. Contineum Therapeutics's Goodwill for the quarter that ended in Sep. 2024 was $0.00 Mil. Contineum Therapeutics's Total Assets for the quarter that ended in Sep. 2024 was $216.03 Mil.


Contineum Therapeutics Goodwill-to-Asset Historical Data

The historical data trend for Contineum Therapeutics's Goodwill-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Contineum Therapeutics Goodwill-to-Asset Chart

Contineum Therapeutics Annual Data
Trend Dec21 Dec22 Dec23
Goodwill-to-Asset
- - -

Contineum Therapeutics Quarterly Data
Dec21 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Goodwill-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Contineum Therapeutics's Goodwill-to-Asset

For the Biotechnology subindustry, Contineum Therapeutics's Goodwill-to-Asset, along with its competitors' market caps and Goodwill-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Contineum Therapeutics's Goodwill-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Contineum Therapeutics's Goodwill-to-Asset distribution charts can be found below:

* The bar in red indicates where Contineum Therapeutics's Goodwill-to-Asset falls into.



Contineum Therapeutics Goodwill-to-Asset Calculation

Goodwill to Asset ratio measures how much goodwill a company is recording compared to the total level of its assets.

It is calculated by dividing goodwill by total assets.

Contineum Therapeutics's Goodwill to Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Goodwill to Asset (A: Dec. 2023 )=Goodwill/Total Assets
=0/130.386
=0.00

Contineum Therapeutics's Goodwill to Asset Ratio for the quarter that ended in Sep. 2024 is calculated as

Goodwill to Asset (Q: Sep. 2024 )=Goodwill/Total Assets
=0/216.034
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Contineum Therapeutics  (NAS:CTNM) Goodwill-to-Asset Explanation

If the goodwill-to-asset ratio increases, it can mean that the company is recording a proportionately higher amount of goodwill, assuming total assets are remaining constant. It is generally good to see a company increasing its assets regularly; however, if these increases are coming from intangible assets, such as goodwill, the increases may not be as good.

Increases in the goodwill-to-asset ratio might suggest that a company has been aggressively acquiring other firms or has seen its tangible assets decrease in value. When a large portion of total assets are attributable to intangible assets (such as goodwill), the company may be at risk of having that portion of its asset base wiped out quickly if it must record any goodwill impairments. Decreases in the goodwill-to-assets ratio suggest that the company has either written down some goodwill or increased its tangible assets.

Asset needs vary from industry to industry. This is why comparing goodwill-to-assets ratios is generally most meaningful among companies within the same industry. By comparing a company's goodwill to assets ratio to those of other companies within the same industry, investors can get a feel for how a company is managing its goodwill.


Contineum Therapeutics Goodwill-to-Asset Related Terms

Thank you for viewing the detailed overview of Contineum Therapeutics's Goodwill-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Contineum Therapeutics Business Description

Comparable Companies
Traded in Other Exchanges
N/A
Address
10578 Science Center Drive, Suite 200, San Diego, CA, USA, 92121
Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS.